Phase II study of SU5416—a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor—in patients with refractory myeloproliferative diseases
Francis J. Giles, Maureen A. Cooper, Lewis Silverman, Judith E. Karp, Jeffrey E. Lancet, Maurizio Zangari, Paul J. Shami, Khuda D. Khan, Alison L. Hannah, Julie M. Cherrington, Deborah A. Thomas, GuilVolume:
97
Year:
2003
Language:
english
Pages:
9
DOI:
10.1002/cncr.11315
File:
PDF, 104 KB
english, 2003